Targeting this pathway—such as with inhibitors disrupting TvAP65-SPCS1 interaction or neutralizing TvAP65 antibodies—may prevent or reduce co-infection by T. vaginalis and HPV, thereby lowering cervical cancer risk. The gene discussed is SPCS1; the disease is cervical carcinoma.